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The role of cytomegalovirus (CMV)–specific cytotoxic T lymphocytes (CTLs) and T helper
cells (Th) in controlling CMV infection, as detected by antigenemia assay and polymerase
chain reaction (PCR) in blood leukocytes, and CMV disease was investigated in 20 renal
transplant recipients. Within 3 months after transplant, CMV-specific CTL and Th responses
were demonstrable in 11 (55%) and 15 (75%) patients, respectively; CMV infection was detected
by antigenemia and PCR in 19 (95%) patients each. During the month of first CMV detection,
there was an inverse correlation between CTL response and antigenemia at >20 positive cells/
105 leukocytes ( ) but no association with lower antigenemia levels or PCR positivity.P 5 .007
CMV disease developed in 7 (35%) patients and was associated with high-level antigenemia
but was inversely correlated with detection of CTLs ( ). After renal transplantation,P 5 .04
CMV-specific CTLs limit the systemic virus load as reflected by antigenemia levels and thereby
mediate protection from CMV disease.
Renal transplant recipients are at increased risk for cyto-
megalovirus (CMV) infection and disease during the posttrans-
plant period, when they require intensive immunosuppressive
regimens for prevention of and therapy for graft rejection [1,
2]. The highest rates of CMV infection are observed among
pretransplant CMV-seropositive and -seronegative patients
with a seropositive kidney donor, and primary CMV disease is
generally more frequent and severe than disease due to reac-
tivation or reinfection [1–4].
The nature of the specific immunologic defects predisposing
organ transplant recipients to CMV infection and CMV disease
have been partially elucidated. Studies among patients after
bone marrow or peripheral blood stem cell transplantation doc-
umented a protective effect of CMV-specific cytotoxic T lym-
phocytes (CTLs) obtained from peripheral blood [5–8]. Among
autograft recipients, the presence of a CMV-specific major his-
tocompatibility complex (MHC) class I–restricted CTL re-
sponse was associated with prevention of CMV infection,
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whereas in the more profoundly immunodeficient allograft re-
cipients, this CTL response did not correlate with suppression
of CMV infection but protected against serious CMV disease
[6, 7]. In renal transplant recipients, data on cytolytic T cell
immunity to CMV are limited and were generated before the
introduction of aggressive immunosuppressive regimens, which
include cyclosporine and antithymocyte globulin (ATG) [9].
In recent years, rapid and sensitive methods for the detection
of CMV in peripheral blood polymorphonuclear leukocytes
(PMNL) by antigenemia assay or by polymerase chain reaction
(PCR) were introduced and shown to recognize CMV infection
in blood at an early stage, when the systemic virus load is still
low [10–15]. The role of the specific T cell immunity during this
early phase of CMV infection is unknown. The present study
characterizes the MHC-restricted T cell immunity in renal
transplant recipients and evaluates the association of CMV-
specific CTL and T helper cell (Th) responses with the presence
of CMV in peripheral blood PMNL as detected by antigenemia
assay and PCR. These immune functions were also correlated
with CMV disease that occurs in the first 3 months after renal
transplantation.
Patients and Methods
Patient population. The investigation was conducted prospec-
tively among 20 recipients of cadaveric donor or living–related
donor kidney transplants at University Hospital, Basel, Switzer-
land. Patients were selected for study if they were seropositive for
CMV IgG antibody before transplantation or were seronegative
with a seropositive kidney donor. Characteristics of the study pop-
ulation are summarized in table 1. After renal transplantation, all
patients received combined immunosuppressive induction treat-
ment with cyclosporine, azathioprine, prednisolone, and ATG.
Three patients required additional ATG for therapy of steroid-
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Table 1. Characteristics of the 20 renal transplant recipients in
whom cytomegalovirus (CMV)–specific T cell immunity and occur-
rence of CMV infection and disease were studied within 3 months
after transplantation.
Characteristic No. (range)
Median age in years 48 (19–69)
Sex (male/female) 9/11
Type of transplant
Cadaveric donor 15
Living–related donor 5
Pretransplant CMV serology
Donor1/recipient1 11
Donor2/recipient1 7
Donor1/recipient2 2
Patients alive 3 months after transplantation 20
resistant graft rejection. CMV-seronegative blood products were
used for transfusion. No subject received prophylactic or preemp-
tive treatment of CMV infection with acyclovir, ganciclovir, or
foscarnet.
Generation of CMV-specific CTLs in vitro. Patients were eval-
uated for the presence of CMV-specific CTLs in peripheral blood
immediately before transplantation and at 1, 2, and 3 months after
transplantation. CMV-specific CTLs were cultured and expanded
in vitro as described [6, 7]. In brief, skin biopsies were obtained
from each patient, to establish fibroblast lines for use as both stim-
ulator and target cells. Fibroblast lines were grown in Waymouth’s
medium (Gibco BRL/Life Technologies, Basel, Switzerland) sup-
plemented with 20% heat-inactivated fetal calf serum (FCS), 2
mmol/L of L-glutamine, 50 U/mL of penicillin, and 50 mg/mL of
streptomycin. Autologous fibroblasts were plated in 6-well plates
at cells/well and infected for 2 h with the human CMV60.5 3 10
AD169 strain (American Type Culture Collection, Rockville, MD)
at an MOI of 5 before initiation of lymphocyte culture.
Peripheral blood mononuclear cells (PBMC) obtained by His-
topaque (Sigma, Buchs, Switzerland) gradient centrifugation were
resuspended in RPMI-HEPES (Gibco BRL) supplemented with
10% CMV-seronegative human AB serum, mol/L of 2-252.5 3 10
mercaptoethanol, 2 mmol/L of L-glutamine, 50 U/mL of penicillin,
and 50 mg/mL of streptomycin and were dispensed at 107 cells/well
in the 6-well plates containing autologous CMV-infected fibroblast
stimulators. After 7 days of incubation at 377C in a humidified 5%
CO2 atmosphere, the cultured cells were harvested, washed, and
recultured at a ratio of 20:1 with fresh CMV-infected fibroblast
stimulators and supplemented with autologous irradiated (3′ 500
cGy) PBMC as filler cells. Two days later, recombinant interleukin-
2 (Becton Dickinson, Bedford, MA) was added to the cultures, to
achieve a final concentration of 2 U/mL. As demonstrated in our
earlier studies [6, 7] and by others [8, 16–19], this cell culture system
results in preferential activation and expansion of CMV-specific
MHC class I–restricted CTLs with a CD31, CD81, CD42
phenotype.
Cytotoxicity assay. Two weeks after initiation of lymphocyte
cultures, the cytotoxicity of the effector cells was assessed by 4-h
51Cr release assay. The panel of targets used for each assay included
autologous and MHC class I–mismatched CMV-infected and
mock-infected fibroblasts as reported [6, 7]. Fibroblast targets were
incubated before use for 48 h with recombinant interferon-g (Sche-
ring, Kenilworth, NJ) at 800 U/106 cells to enhance MHC class I
expression and thereby the sensitivity of the cytotoxicity assay [17].
The targets were then labeled overnight with 51Cr at 100 mCi/106
cells (Amersham Laboratories, Amersham, UK), and an aliquot
was infected with CMV AD169 at an MOI of 5. Labeled targets
were harvested and suspended at 105 cells/mL in RPMI with 10%
FCS, and 100 mL (104 cells) was dispensed in triplicate into 96-well
round-bottom plates, together with 100 mL of effector cell suspen-
sion at an effector-to-target ratio of 15:1. Cytotoxicity was also
simultaneously assayed against targets preincubated with the
anti–class I monoclonal antibody W6/32 (provided by G. De Lib-
ero, Department of Research, University Hospital, Basel) to con-
firm MHC class I restriction of target cell lysis [6, 18]. After in-
cubation for 4 h, 100 mL of supernatant was harvested from each
well, and radioactivity was measured in a gamma counter.
Specific cytotoxicity was calculated by the standard formula,
with maximum release reflecting counts per minute (cpm) from
incubation of target cells with 1% Nonidet P40-solution and spon-
taneous release, which never exceeded 30% of maximum release,
reflecting cpm following incubation of targets with medium alone.
Investigations in 5 CMV-seropositive healthy volunteers showed a
median specific lysis of autologous CMV-infected fibroblasts of
34% (range, 28%–53%; data not shown). Based on our previous
results, a CMV-specific CTL response was considered positive if
lysis of autologous CMV-infected fibroblast targets was 15% above
the level of lysis obtained with autologous mock-infected and MHC
class I–mismatched CMV-infected and mock-infected targets [6, 7].
Lymphoproliferative assay. The proliferative response to sol-
uble CMV antigen, which reflects the CMV-specific MHC class
II–restricted CD41 Th response [8, 20], and to phytohemagglutinin
(PHA) was assessed each time a CTL culture was initiated as de-
scribed [6, 7]. In brief, PBMC were suspended at 106 cells/mL in
lymphocyte culture medium, and 100 mL was dispensed in triplicate
into wells of 96-well round-bottom plates. Soluble CMV antigen
or PHA (Murex Diagnostics Benelux, Schaffhausen, Switzerland)
was added at final concentrations of 1:100 and 10 mg/mL, respec-
tively, and the plates were incubated at 377C in a humidified 5%
CO2 atmosphere for 96 h. The cells were pulsed with 1 mCi/well of
[3H]thymidine (Amersham Laboratories) 16 h before harvest. The
wells were then harvested and samples measured in a b-scintillation
counter. Results were expressed as a stimulation index calculated
by dividing the mean cpm of cells exposed to CMV antigen or to
PHA by the mean cpm of cells incubated with medium alone. A
stimulation index >4 indicated a positive lymphoproliferative re-
sponse [7].
Detection of CMV in blood by antigenemia assay and by PCR.
Patients were monitored for detection of CMV in PMNL by both
antigenemia assay and nested PCR once before transplantation and
at weekly intervals during the first 3 months after transplantation.
While the antigenemia assay was done on the day of blood sam-
pling, the specimens for PCR were cryopreserved and processed
after study completion. For the antigenemia assay, 105 PMNL were
cytocentrifuged in triplicate on microscopic glass slides and incu-
bated at room temperature for 1 h with the anti-pp65 monoclonal
antibodies C-10 and C-11 (Clonab; Biotest, Dreieich, Germany)
[10]. The slides were then incubated with biotinylated horse anti-
mouse serum for 30 min. We used the avidin-biotin complex tech-
nique for visualization of the product using the ABC-elite kit ac-
cording to the protocol of the manufacturer (Vector, Burlingame,
JID 1999;180 (August) T Cell Immunity to CMV after Renal Transplant 249
CA). The immunoperoxidase reaction was visualized using 3-
amino-9-ethylcarbazole (Sigma) and was counterstained with he-
matoxylin. Slides were screened by light microscopy, and the result
was expressed as the number of antigen-positive cells/105 stained
PMNL.
For the nested PCR, DNA was extracted from PMNL by di-
gesting the cell pellet overnight in a buffer containing 1% SDS and
1 mg/mL of proteinase K, which was followed by phenol/chloro-
form extraction and precipitation of the DNA by ethanol. The
pellet was then dissolved in H2O. A DNA equivalent of 10
5 cells
measured by fluorometer (Hoefer Scientific Instruments, San Fran-
cisco) was used in the first round of the nested PCR assay, which
contained 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl2,
1 mM sense and antisense primer, 200 mM of each dNTP, and 1.25
U of AmpliTaq DNA polymerase (Perkin Elmer, Ueberlingen, Ger-
many). Primers for the major immediate early gene region of CMV
were used. In the first PCR round, the upstream sense primer
MIE2783 (5′-CGCCGCATTGAGGAGATCTGC) and the anti-
sense downstream primer MIE-5 (5′-CACCACCATCCTCCT-
CTTCCTCTGG) were applied [21]. One percent of the product
of the first round was transferred to the second PCR reaction
using the sense upstream primer IE-1 (5′-CCACCCGTGGTG-
CCAGCTCC) and the antisense downstream primer MIE3114 (5′-
GACTTGACAGACACAGTG), leading to a final PCR product
of 183 bp [21]. Thirty cycles were performed in both PCR rounds,
with the following cycle conditions: denaturation for 1 min at 947C,
reanealing for 1 min at 557C, and extension for 55 s at 727C, with
a final extension step in the last round of 7 min at 727C. All PCR
products were analyzed on a 2% agarose gel and visualized by
ethidium bromide stain in a UV illuminator.
Definition of CMV infection and CMV disease. CMV infection
was defined as positive CMV antigenemia or detection of CMV
by viral cultures or histology in clinical specimens collected at the
discretion of the primary care physicians. Since the PCR results
were not available for clinical decision-making, they were not used
to define CMV infection. The definition of CMV disease included
both a CMV syndrome and CMV organ disease. The CMV syn-
drome was considered present if CMV infection was associated
with unexplained fever 1387C for >3 days with one of the following
factors: leukopenia ! /mL, thrombocytopenia !105/mL, serum33 3 10
alanine aminotransferase >2.5 times the upper limit of normal,
atypical lymphocytosis 120%, or interstitial infiltrates on chest ra-
diograph [22–24]. CMV organ disease required the evidence of
CMV in tissue specimens or for CMV pneumonia in bronchoal-
veolar lavage fluid, with associated symptoms and signs.
Statistical analyses. Comparisons between multiple groups
were done by one-way analysis of variance on ranks and the Krus-
kal-Wallis test. For comparison of two groups, the Wilcoxon rank
sum test was used for continuous variables, and Fisher’s exact test
was used for dichotomous variables. was consideredP ! .05
significant.
Results
CMV-specific CTL response. Before transplantation, a
CMV-specific CTL activity was detectable in 12 (67%) of the
18 CMV-seropositive patients and was undetectable in the 2
seronegative patients. Within 3 months after renal transplan-
tation, the presence of a CMV-specific CTL response was de-
monstrable in 11 (55%) of 20 patients. Of the 12 patients with
pretransplant CTL activity, 8 had a detectable CMV-specific
CTL response in the first 3 months after transplantation, and
4 did not. Among the 8 patients without a CTL response specific
for CMV before transplantation, 3 developed this response dur-
ing the posttransplant course (including 1 of the 2 pretransplant
CMV-seronegative patients), and 5 did not.
The lytic activity against autologous CMV-infected target
cells was significantly higher than the level of cytotoxicity
against autologous mock-infected or MHC class I–mismatched
CMV-infected and mock-infected targets before transplantation
( ) and at 1 ( ), 2 ( ), and 3 months (P ! .001 P 5 .03 P 5 .01 P !
) after transplantation (figure 1). The preferential lysis of.001
autologous CMV-infected fibroblast targets over MHC-mis-
matched infected targets at all time points indicates that the
culture system used generated classical MHC class I–restricted
CTL specific for CMV. This was further supported by the effect
of the anti–class I monoclonal antibody W6/32, which reduced
lysis of autologous CMV-infected fibroblast targets on average
by 59% ( ; data not shown). Compared with the pre-P ! .001
transplant results, the magnitude of CMV-specific CTL activity
was significantly decreased at 1 month ( ) and 2 monthsP 5 .002
( ) after renal transplantation but was similar 3 monthsP 5 .01
after transplant (figure 1).
Lymphoproliferative response to CMV and to PHA. Before
transplantation, lymphoproliferation to CMV antigen, which
reflects the specific CD41 Th function, was detectable in 14
(70%) of 20 patients, and a proliferative response to PHA was
present in 19 (95%) patients (figure 2). Within 3 months after
transplantation, a lymphoproliferative response to CMV an-
tigen was demonstrable in 15 (75%) patients, and lymphopro-
liferation to PHA was detectable in all patients (figure 2). The
proliferative response to CMV antigen was significantly de-
pressed at 1 ( ) and 2 months ( ) but not at 3P 5 .007 P 5 .01
months after transplantation, compared with pretransplant val-
ues (figure 2). Lymphoproliferation to PHA was significantly
weaker at 1 ( ), 2 ( ) and 3 months ( )P 5 .01 P 5 .03 P 5 .008
after transplantation, compared with the pretransplantation re-
sponse (figure 2). All patients who had a demonstrable CMV-
specific CTL activity after transplantation had a positive lym-
phoproliferative response to CMV antigen by the time of first
CTL detection. There was a significant correlation between si-
multaneous presence or absence of these two immune functions
( ).P ! .001
CMV antigenemia and PCR-based detection of CMV DNA
in blood. CMV antigenemia occurred in 19 (95%) of 20 pa-
tients within the first 3 months after renal transplantation. Me-
dian (range) time to first detection of CMV antigenemia was
26 days (10–48) after transplant. Sixteen (80%) patients had
antigenemia levels >10 cells, 13 (65%) had >20 cells, and 10
(50%) had >50 cells. All patients in whom CMV was docu-
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Figure 1. Cytotoxicity of cells from renal transplant recipients with detectable cytomegalovirus (CMV)–specific major histocompatibility complex
(MHC) class I–restricted cytotoxic T lymphocyte (CTL) response. This CTL response was demonstrable in 12 patients before and in 11 within
3 months after transplantation. Cytotoxicity was assayed at effector-to-target ratio of 15:1 against autologous CMV-infected (A) and mock-
infected (B) fibroblast targets and against MHC class I–mismatched CMV-infected (C) and mock-infected (D) fibroblast targets. Horizontal bar,
median.
mented at sites other than blood had previous positive CMV
antigenemia. During the posttransplant course, CMV DNA in
PMNL was detected by PCR in 19 (95%) of 20 patients at a
median (range) of 23 (8–46) days after transplantation, which
was not significantly earlier than the occurrence of the first
positive CMV antigenemia.
CMV antigenemia and CMV disease. During the post-
transplant study period, 9 episodes of CMV disease occurred
in 7 (35%) of 20 patients. Eight of these 9 episodes were di-
agnosed as CMV syndrome and 1 as CMV pneumonia. Median
(range) onset of the first episode of CMV disease was on day
29 (23–70) after transplantation. There was no association be-
tween occurrence of a first episode of CMV disease and CMV
antigenemia at any number of positive cells. However, a first
episode of CMV disease developed in 7/13 patients with CMV
antigenemia at >20 positive cells/105 PMNL but in none of the
7 patients with lower antigenemia levels ( ).P 5 .04
CMV-specific T cell immunity and CMV infection and dis-
ease. When the association of CMV-specific CTL response
with detection of CMV in blood by antigenemia assay or by
PCR was evaluated independently from the timing of these
events within 3 months after transplantation, no correlation
between these variables was found. Because the degree of im-
munosuppression may vary during the posttransplant course,
a time-dependent analysis was done in which the occurrence of
CMV antigenemia and of PCR positivity was correlated with
the specific CTL response at the end of the month when CMV
infection was first detected by these diagnostic assays. During
the month of first positive CMV antigenemia, there was no
association between CMV-specific CTL response and anti-
genemia at any number of positive cells. In fact, there was an
inverse correlation between specific CTL activity and CMV
antigenemia at >20 positive cells/105 PMNL ( ; tableP 5 .007
2). During the month of the first positive PCR in blood, no
statistically significant association was found between CTL re-
sponse and PCR positivity. Of importance, during the month
of a first episode of CMV disease, the CMV-specific CTL re-
sponse was inversely correlated with the occurrence of CMV
disease ( ; table 3).P 5 .04
Similar analyses were performed to evaluate the association
of a CMV-specific Th response with the occurrence of CMV
antigenemia or PCR positivity for CMV in blood and with the
development CMV disease after transplantation. There was no
statistically significant correlation between these variables
whether the timing of events was considered or not (data not
shown).
Discussion
This study characterizes the CMV-specific CTL and Th re-
sponses in renal transplant recipients and defines the role of
these effector cells in controlling both CMV infection, as de-
tected by antigenemia and PCR in peripheral blood, and CMV
disease. A CMV-specific MHC class I–restricted CTL activity
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Table 2. Cytomegalovirus (CMV)–specific major histocompatibility
complex class I–restricted CTL response at the end of the month during
which CMV antigenemia was first detected at >20 positive cells/105
PMNL within 3 months after renal transplantation.
CTL response CMV antigenemia No. of patients P
1 2 5
1 1 1 .007
2 1 12
2 2 2
NOTE. CTL, cytotoxic T lymphocyte; PMNL, polymorphonuclear
leukocytes.
Figure 2. Lymphoproliferative responses to cytomegalovirus (CMV) antigen and to phytohemagglutinin (PHA) among 20 renal transplant
recipients. Stimulation index (SI) was calculated as described under Patients and Methods; SI > 4.0 was considered positive. Horizontal bar,
median.
was demonstrable in 55% of patients in the first 3 months after
transplantation and was associated with protection from high-
level CMV antigenemia and from CMV disease.
Within 3 months after transplantation, CMV antigenemia
developed in 95% of our patients. The antigenemia assay used
for early detection of CMV infection is based on recognition
of the lower matrix protein pp65 of CMV, which is present in
blood leukocytes during active CMV infection [10, 14, 15, 25].
The number of antigen-positive cells in blood furthermore re-
flects the systemic virus load, and high CMV antigenemia levels
were shown to predict CMV disease in renal transplant recip-
ients [12, 14, 15]. Investigations of the fine specificity of T cell
responses to human CMV identified the CMV pp65 antigen as
a major target for both CTL [26, 27] and Th cells [28–31]. Thus,
the evaluation of the relationship between T cell responses spe-
cific for CMV in blood and CMV antigenemia provides infor-
mation on the effects of an immunodominant part of T cell
immunity on the occurrence of CMV infection and on the in-
crease in systemic virus load up to levels at which patients carry
an elevated risk for CMV disease.
During the month of the first positive CMV antigenemia, we
found no correlation between CMV-specific CTL response and
antigenemia at any number of positive cells. Thus, CTLs spe-
cific for CMV did not prevent CMV infection that usually
results from reactivation of latent virus in the host or from
acquisition of exogenous virus strains from the organ donor [3,
4]. The CMV-specific CTL response, however, was associated
with protection from high-level antigenemia at >20 positive
cells/105 PMNL. Thus, in the period in which renal transplant
recipients require intensive immunosuppression for prophylaxis
or therapy of graft rejection, these effector cells appear to con-
trol CMV infection by limiting the systemic virus load.
The lack of correlation in our study between PCR-based
detection of CMV DNA in blood PMNL and the presence of
CTLs specific for CMV is consistent with the results observed
at low levels of antigenemia. The median times to first positive
CMV antigenemia and PCR in PMNL were similar, which
suggests that both methods had a comparable sensitivity in
detecting early CMV infection in blood. No attempt was made
to quantify the virus load by PCR. Our results indicate that
the occurrence of CMV infection as diagnosed by qualitative
PCR in peripheral blood PMNL is not prevented by CMV-
specific CTLs within 3 months after renal transplantation.
An increased systemic virus load as reflected by the antige-
nemia assay predisposes to CMV disease after renal transplan-
tation. Our data confirm the earlier observation that a cutoff
level of 20 antigen-positive cells/105 PMNL differentiates be-
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Table 3. Cytomegalovirus (CMV)–specific major histocompatibility
complex class I–restricted CTL response at the end of the month of a
first episode of CMV disease within 3 months after renal
transplantation.
CTL response CMV disease No. of patients P
1 2 7
1 1 0 .04
2 1 7
2 2 6
NOTE. CTL, cytotoxic T lymphocyte.
tween low and high risk for CMV disease [12, 14]. Most im-
portantly, CMV-specific CTLs in our patients mediated pro-
tection from CMV disease in the first 3 months after
transplantation. The control of systemic virus load by this arm
of T cell immunity thus appears to be pivotal in the prevention
of CMV disease in renal transplant recipients.
In contrast, the presence of a Th response to CMV was
neither associated with protection against high-level CMV anti-
genemia or PCR positivity in blood nor from CMV disease,
although this immune function was demonstrable in 75% of
our patients during the posttransplant course. However, anti-
gen-specific Th cells seemed to play an important role in the
generation of a CMV-specific CTL activity, which is consistent
with similar findings among recipients of allogeneic or autol-
ogous bone marrow and peripheral blood stem cell transplants
[6, 7, 32].
With the cell culture system used in the present investigation,
MHC class I–restricted CTL specific for CMV are readily de-
tectable in healthy CMV-seropositive persons who show no
evidence of viral reactivation [6, 16, 18, 19]. Only 67% of our
CMV-seropositive patients had a demonstrable CMV-specific
CTL response before transplantation. In the pretransplant pe-
riod, all patients required long-term dialysis. Impaired Th func-
tions have been observed in persons with chronic renal failure
and were not improved by hemodialysis [33, 34]. Studies of the
effects of chronic renal failure on CMV-specific CTL activity
have not been reported to date. Our results indicate that pa-
tients with chronic renal failure who receive long-term dialysis
have a deficient CTL immunity to CMV. The fact that CMV
infection nevertheless occurs in most cases after renal trans-
plantation suggests that allogeneic stimulation or more pro-
found immunosuppression are necessary to reactivate CMV.
In conclusion, our data indicate that the CMV-specific MHC
class I–restricted CTL response plays a crucial role in protecting
renal transplant recipients from serious CMV infection by lim-
iting the systemic virus load and thereby reducing the risk for
CMV disease. By contrast, Th cell immunity to CMV does not
seem directly involved in suppressing CMV infection but is
essential for the generation of a specific CTL activity in these
patients. Our results could have implications for the adoptive
immunotherapy with virus-specific CTL clones, which is a
promising approach to the prevention of viral infections in im-
munodeficient hosts [32, 35]. The CTL response to CMV in
our patients afforded protection from high-level CMV anti-
genemia, which infers that an important proportion of these
effector cells in peripheral blood recognizes the pp65 antigen
of CMV. Adoptive immunotherapy with CMV-specific T cell
clones would be greatly facilitated if future investigations dem-
onstrate that the exclusive transfer of clones against this CMV
antigen mediates sufficient protection from CMV infection and
CMV disease in immunocompromised patients.
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